Zafgen Company Profile (NASDAQ:ZFGN)

About Zafgen (NASDAQ:ZFGN)

Zafgen logoZafgen, Inc. is a biopharmaceutical company. The Company is focused on improving the health and well-being of patients affected by obesity and complex metabolic disorders. The Company's lead product candidate, Beloranib, is a twice-weekly subcutaneous injection being developed for the treatment of multiple indications, including severe obesity in rare diseases, such as Prader-Willi syndrome (PWS) and hypothalamic injury-associated obesity (HIAO), including craniopharyngioma-associated obesity. Beloranib is in Phase III stage of development for PWS. It is also developing ZGN-839, a liver-targeted methionine aminopeptidase 2 (MetAP2) inhibitor, for the treatment of nonalcoholic steatohepatitis (NASH) and abdominal obesity, as well as other second-generation MetAP2 inhibitors for the treatment of severe obesity. It is also evaluating additional MetAP2 inhibitors beyond Beloranib as a development candidate for the treatment of severe obesity in the general population.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Bio Therapeutic Drugs
  • Sub-Industry: N/A
  • Symbol: NASDAQ:ZFGN
  • CUSIP: N/A
  • Web: www.zafgen.com
Capitalization:
  • Market Cap: $92.07 million
  • Outstanding Shares: 27,483,000
Average Prices:
  • 50 Day Moving Avg: $3.46
  • 200 Day Moving Avg: $3.97
  • 52 Week Range: $2.89 - $5.46
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -2.39
  • P/E Growth: 0.00
Sales & Book Value:
  • Annual Revenue: N/A
  • Price / Sales: N/A
  • Book Value: $3.63 per share
  • Price / Book: 0.91
Profitability:
  • EBIDTA: ($50,510,000.00)
  • Return on Equity: -44.54%
  • Return on Assets: -40.97%
Debt:
  • Current Ratio: 11.72%
  • Quick Ratio: 11.72%
Misc:
  • Average Volume: 166,648 shs.
  • Beta: -1.36
  • Short Ratio: 2.51
 

Frequently Asked Questions for Zafgen (NASDAQ:ZFGN)

What is Zafgen's stock symbol?

Zafgen trades on the NASDAQ under the ticker symbol "ZFGN."

How were Zafgen's earnings last quarter?

Zafgen, Inc. (NASDAQ:ZFGN) posted its earnings results on Tuesday, August, 8th. The company reported ($0.49) EPS for the quarter, beating the consensus estimate of ($0.52) by $0.03. During the same period in the previous year, the business posted ($0.55) earnings per share. View Zafgen's Earnings History.

When will Zafgen make its next earnings announcement?

Zafgen is scheduled to release their next quarterly earnings announcement on Tuesday, November, 7th 2017. View Earnings Estimates for Zafgen.

Where is Zafgen's stock going? Where will Zafgen's stock price be in 2017?

2 analysts have issued 1-year target prices for Zafgen's shares. Their predictions range from $9.00 to $9.00. On average, they anticipate Zafgen's stock price to reach $9.00 in the next twelve months. View Analyst Ratings for Zafgen.

Who are some of Zafgen's key competitors?

Who are Zafgen's key executives?

Zafgen's management team includes the folowing people:

  • Peter Barrett Ph.D., Independent Chairman of the Board
  • Thomas E. Hughes Ph.D., President, Chief Executive Officer, Director
  • Patricia L. Allen CPA, Chief Financial Officer
  • Dennis D. Kim M.D., Chief Medical Officer
  • Bruce L. Booth Ph.D., Director
  • Thomas O. Daniel M.D., Director
  • Geoffrey McDonough M.D., Director
  • Robert J. Perez, Director
  • Frances K. Heller J.D., Independent Director

Who owns Zafgen stock?

Zafgen's stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include FMR LLC (14.87%), Artal Group S.A. (3.65%), Vanguard Group Inc. (3.23%), Dimensional Fund Advisors LP (2.13%), Royce & Associates LP (1.21%) and Spark Investment Management LLC (1.03%). Company insiders that own Zafgen stock include Dennis D Kim, Frances K Heller, James E Flynn, Kevin P Starr, Patricia L Allen and Thomas E Hughes. View Institutional Ownership Trends for Zafgen.

Who sold Zafgen stock? Who is selling Zafgen stock?

Zafgen's stock was sold by a variety of institutional investors in the last quarter, including Northern Trust Corp, TIAA CREF Investment Management LLC, Bank of New York Mellon Corp, Royce & Associates LP, Candriam Luxembourg S.C.A. and Royal Bank of Canada. View Insider Buying and Selling for Zafgen.

Who bought Zafgen stock? Who is buying Zafgen stock?

Zafgen's stock was purchased by a variety of institutional investors in the last quarter, including Goldman Sachs Group Inc., Dimensional Fund Advisors LP, Vanguard Group Inc., OxFORD Asset Management LLP, Spark Investment Management LLC, Acadian Asset Management LLC, LMR Partners LLP and GSA Capital Partners LLP. Company insiders that have bought Zafgen stock in the last two years include Dennis D Kim, Frances K Heller, James E Flynn, Patricia L Allen and Thomas E Hughes. View Insider Buying and Selling for Zafgen.

How do I buy Zafgen stock?

Shares of Zafgen can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Zafgen's stock price today?

One share of Zafgen stock can currently be purchased for approximately $3.32.


MarketBeat Community Rating for Zafgen (NASDAQ ZFGN)
Community Ranking:  3.0 out of 5 (star star star)
Outperform Votes:  165 (Vote Outperform)
Underperform Votes:  112 (Vote Underperform)
Total Votes:  277
MarketBeat's community ratings are surveys of what our community members think about Zafgen and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Zafgen (NASDAQ:ZFGN) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 1 Hold Rating, 1 Buy Rating
Consensus Rating:Buy (Score: 2.50)
Consensus Price Target: $9.00 (171.08% upside)

Analysts' Ratings History for Zafgen (NASDAQ:ZFGN)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
4/20/2017Roth CapitalInitiated CoverageBuy -> Buy$9.00HighView Rating Details
3/10/2017Cowen and CompanyReiterated RatingHoldN/AView Rating Details
3/7/2017FBR & CoReiterated RatingMarketperformLowView Rating Details
7/21/2016Canaccord GenuitySet Price TargetHold$7.00 -> $4.00N/AView Rating Details
7/20/2016Leerink SwannReiterated RatingMarket Perform$6.00N/AView Rating Details
4/5/2016Royal Bank Of CanadaReiterated RatingOutperform$19.00N/AView Rating Details
2/20/2016SunTrust Banks, Inc.Reiterated RatingHold$7.00N/AView Rating Details
10/16/2015JMP SecuritiesDowngradeOutperform -> Market PerformN/AView Rating Details
(Data available from 9/22/2015 forward)

Earnings

Earnings History for Zafgen (NASDAQ:ZFGN)
Earnings by Quarter for Zafgen (NASDAQ:ZFGN)
Earnings History by Quarter for Zafgen (NASDAQ ZFGN)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/7/2017($0.58)N/AView Earnings Details
8/8/2017Q2 2017($0.52)($0.49)ViewListenView Earnings Details
5/9/2017Q1 2017($0.43)($0.48)ViewN/AView Earnings Details
3/9/2017Q4 2016($0.50)($0.38)ViewListenView Earnings Details
5/10/2016Q116($0.74)($0.65)ViewListenView Earnings Details
3/9/2016Q415($0.80)($0.85)ViewN/AView Earnings Details
11/10/2015Q3($0.79)($0.73)$80.60 million$78.20 millionViewListenView Earnings Details
8/11/2015Q215($0.71)($0.66)ViewListenView Earnings Details
5/12/2015Q115($0.52)($0.53)ViewListenView Earnings Details
3/19/2015Q414($0.84)($0.48)ViewListenView Earnings Details
11/11/2014Q314($0.87)($0.65)ViewN/AView Earnings Details
8/13/2014Q214($0.28)($2.96)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Zafgen (NASDAQ:ZFGN)
2017 EPS Consensus Estimate: ($2.24)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20172($0.49)($0.41)($0.45)
Q2 20172($0.58)($0.53)($0.56)
Q3 20172($0.64)($0.54)($0.59)
Q4 20172($0.70)($0.59)($0.65)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Zafgen (NASDAQ:ZFGN)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Zafgen (NASDAQ:ZFGN)
Insider Ownership Percentage: 21.20%
Institutional Ownership Percentage: 48.52%
Insider Trades by Quarter for Zafgen (NASDAQ:ZFGN)
Institutional Ownership by Quarter for Zafgen (NASDAQ:ZFGN)
Insider Trades by Quarter for Zafgen (NASDAQ:ZFGN)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
7/11/2017Dennis D KimInsiderBuy10,000$3.39$33,900.00View SEC Filing  
5/11/2017Dennis D. KimInsiderBuy10,000$4.40$44,000.00View SEC Filing  
12/19/2016Frances K HellerDirectorBuy10,000$3.23$32,300.00View SEC Filing  
11/15/2016Frances K HellerDirectorBuy10,000$3.54$35,400.00View SEC Filing  
8/29/2016Thomas E HughesInsiderBuy10,000$3.00$30,000.00View SEC Filing  
7/26/2016Patricia L. AllenCFOBuy16,000$3.12$49,920.00View SEC Filing  
7/22/2016Frances K HellerDirectorBuy10,000$2.99$29,900.00View SEC Filing  
7/22/2016Thomas E. HughesInsiderBuy5,000$3.02$15,100.00View SEC Filing  
2/12/2016James E FlynnInsiderBuy64,545$6.25$403,406.25View SEC Filing  
2/11/2016James E FlynnInsiderBuy267,493$6.02$1,610,307.86View SEC Filing  
9/24/2015Kevin P StarrDirectorSell136,579$43.90$5,995,818.10View SEC Filing  
9/18/2015Avi Y GoldbergDirectorSell5,000$45.00$225,000.00View SEC Filing  
9/18/2015Thomas E. HughesCEOSell45,626$42.53$1,940,473.78View SEC Filing  
9/17/2015Dennis D. KiminsiderSell39,407$40.00$1,576,280.00View SEC Filing  
6/10/2015Avi Y GoldbergDirectorSell3,000$35.00$105,000.00View SEC Filing  
6/1/2015Avi Y GoldbergDirectorSell2,000$32.23$64,460.00View SEC Filing  
6/19/2014Alicia SecorInsiderBuy4,000$20.00$80,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Zafgen (NASDAQ:ZFGN)
Latest Headlines for Zafgen (NASDAQ:ZFGN)
Source:
DateHeadline
americanbankingnews.com logoZafgen, Inc. (ZFGN) Lifted to "Buy" at Zacks Investment Research
www.americanbankingnews.com - September 19 at 11:24 AM
americanbankingnews.com logoZafgen, Inc. (ZFGN) Downgraded by Zacks Investment Research
www.americanbankingnews.com - September 15 at 6:46 PM
streetinsider.com logoZafgen (ZFGN) Starts Phase 2 Clinical Trial for ZGN-1061 in Patients with Type 2 Diabetes
www.streetinsider.com - September 14 at 12:06 PM
americanbankingnews.com logoZafgen, Inc. (ZFGN) Stock Rating Upgraded by Zacks Investment Research
www.americanbankingnews.com - September 13 at 12:26 PM
streetinsider.com logoZafgen (ZFGN) Starts Phase 2 Clinical Trial for ZGN-1061 in Patients with Type 2 Diabetes - StreetInsider.com
www.streetinsider.com - September 13 at 1:42 AM
finance.yahoo.com logoZafgen Initiates Phase 2 Clinical Trial for ZGN-1061 in Patients with Type 2 Diabetes
finance.yahoo.com - September 12 at 8:41 PM
streetinsider.com logoZafgen (ZFGN) Announces New Preclinical Data on ZGN-1061 - StreetInsider.com
www.streetinsider.com - September 12 at 12:38 PM
finance.yahoo.com logoZafgen Presents New Preclinical Data on ZGN-1061 at the 53rd Annual Meeting of the European Association for the Study of Diabetes
finance.yahoo.com - September 12 at 12:38 PM
americanbankingnews.com logoZafgen, Inc. (ZFGN) Lowered to Hold at Zacks Investment Research
www.americanbankingnews.com - September 9 at 12:34 PM
americanbankingnews.com logoZafgen, Inc. (ZFGN) Receives Average Recommendation of "Hold" from Analysts
www.americanbankingnews.com - September 6 at 5:16 PM
americanbankingnews.com logoZafgen, Inc. (ZFGN) Stock Rating Lowered by Zacks Investment Research
www.americanbankingnews.com - September 1 at 12:22 PM
americanbankingnews.com logoZafgen, Inc. (ZFGN) Rating Increased to Buy at Zacks Investment Research
www.americanbankingnews.com - August 30 at 6:16 PM
americanbankingnews.com logoZafgen, Inc. (ZFGN) Cut to "Hold" at Zacks Investment Research
www.americanbankingnews.com - August 26 at 10:12 AM
americanbankingnews.com logoZacks: Brokerages Anticipate Zafgen, Inc. (ZFGN) to Post -$0.54 EPS
www.americanbankingnews.com - August 21 at 10:20 PM
americanbankingnews.com logoZafgen, Inc. (NASDAQ:ZFGN) Given Average Recommendation of "Hold" by Analysts
www.americanbankingnews.com - August 12 at 5:02 PM
americanbankingnews.com logoZafgen, Inc. (NASDAQ:ZFGN) Upgraded by Zacks Investment Research to "Buy"
www.americanbankingnews.com - August 12 at 10:00 AM
americanbankingnews.com logoQ3 2017 EPS Estimates for Zafgen, Inc. Increased by Leerink Swann (ZFGN)
www.americanbankingnews.com - August 11 at 7:48 AM
americanbankingnews.com logoZafgen, Inc. (ZFGN) Releases Earnings Results, Beats Estimates By $0.03 EPS
www.americanbankingnews.com - August 10 at 3:22 PM
globenewswire.com logoZafgen Reports Second Quarter 2017 Financial Results - GlobeNewswire (press release)
globenewswire.com - August 9 at 3:29 PM
finance.yahoo.com logoInvestor Network: Zafgen, Inc. to Host Earnings Call
finance.yahoo.com - August 9 at 9:28 AM
finance.yahoo.com logoZafgen Reports Second Quarter 2017 Financial Results
finance.yahoo.com - August 9 at 9:28 AM
finance.yahoo.com logoZafgen reports 2Q loss
finance.yahoo.com - August 9 at 9:28 AM
finance.yahoo.com logoZafgen to Present at the Canaccord Genuity 37th Annual Growth Conference
finance.yahoo.com - August 3 at 9:13 AM
finance.yahoo.com logoZafgen to Host Conference Call to Discuss Second Quarter 2017 Financial Results
finance.yahoo.com - August 2 at 9:03 AM
americanbankingnews.com logoZafgen, Inc. (ZFGN) Scheduled to Post Earnings on Wednesday
www.americanbankingnews.com - July 26 at 7:45 AM
americanbankingnews.com logoZafgen, Inc. (NASDAQ:ZFGN) Receives Consensus Rating of "Hold" from Analysts
www.americanbankingnews.com - July 18 at 5:31 PM
americanbankingnews.com logoZafgen, Inc. (NASDAQ:ZFGN) Short Interest Update
www.americanbankingnews.com - July 16 at 7:14 AM
nasdaq.com logoBUZZ-US STOCKS ON THE MOVE- Yandex, US Retailers, Teva, Tesaro - Nasdaq
www.nasdaq.com - July 13 at 3:33 PM
americanbankingnews.com logoZacks Investment Research Lowers Zafgen, Inc. (ZFGN) to Hold
www.americanbankingnews.com - July 13 at 3:02 PM
americanbankingnews.com logoDennis D. Kim Acquires 10,000 Shares of Zafgen, Inc. (NASDAQ:ZFGN) Stock
www.americanbankingnews.com - July 12 at 8:45 PM
americanbankingnews.com logoZacks: Brokerages Expect Zafgen, Inc. (ZFGN) to Post -$0.53 Earnings Per Share
www.americanbankingnews.com - July 12 at 12:56 PM
americanbankingnews.com logoZafgen, Inc. (ZFGN) Lifted to Sell at ValuEngine
www.americanbankingnews.com - July 8 at 2:20 PM
americanbankingnews.com logoZafgen, Inc. (NASDAQ:ZFGN) Rating Increased to Buy at Zacks Investment Research
www.americanbankingnews.com - July 8 at 9:10 AM
americanbankingnews.com logoZafgen, Inc. (ZFGN) Receives Average Rating of "Hold" from Analysts
www.americanbankingnews.com - June 23 at 2:50 PM
americanbankingnews.com logo Analysts Anticipate Zafgen, Inc. (ZFGN) to Announce -$0.56 Earnings Per Share
www.americanbankingnews.com - June 16 at 12:32 PM
globenewswire.com logoZafgen to Present at the JMP Securities Life Sciences Conference - GlobeNewswire (press release)
globenewswire.com - June 14 at 4:30 PM
finance.yahoo.com logoZafgen to Present at the JMP Securities Life Sciences Conference
finance.yahoo.com - June 14 at 2:29 AM
streetinsider.com logoZafgen (ZFGN) Announces New Data Highlighting Potential of ZGN-1061 for the Treatment of Type 2 Diabetes & Obesity - StreetInsider.com
www.streetinsider.com - June 12 at 6:27 AM
finance.yahoo.com logoZafgen Presents New Data Highlighting Potential of ZGN-1061 for the Treatment of Type 2 Diabetes and Obesity at the American Diabetes Association’s 77th Annual Scientific Sessions
finance.yahoo.com - June 11 at 8:22 AM
finance.yahoo.com logoZafgen to Present Two Late-Breaking Abstracts for ZGN-1061 at the American Diabetes Association 77th Scientific Sessions 
finance.yahoo.com - June 7 at 1:30 AM
americanbankingnews.com logoZafgen Inc (ZFGN) Downgraded by ValuEngine to "Strong Sell"
www.americanbankingnews.com - June 2 at 5:42 PM
americanbankingnews.com logoZafgen Inc (ZFGN) Given Consensus Recommendation of "Hold" by Brokerages
www.americanbankingnews.com - May 29 at 2:58 PM
americanbankingnews.com logoZafgen Inc (ZFGN) Downgraded by Zacks Investment Research
www.americanbankingnews.com - May 13 at 9:04 AM
americanbankingnews.com logoFY2017 EPS Estimates for Zafgen Inc (ZFGN) Raised by Leerink Swann
www.americanbankingnews.com - May 12 at 11:44 AM
americanbankingnews.com logoFY2017 Earnings Estimate for Zafgen Inc Issued By SunTrust Banks (ZFGN)
www.americanbankingnews.com - May 12 at 11:44 AM
americanbankingnews.com logoInsider Buying: Zafgen Inc (ZFGN) Insider Purchases 10,000 Shares of Stock
www.americanbankingnews.com - May 11 at 8:48 PM
globenewswire.com logoZafgen Reports First Quarter 2017 Financial Results - GlobeNewswire (press release)
globenewswire.com - May 11 at 8:26 PM
seekingalpha.com logoZafgen's Second Act
seekingalpha.com - May 11 at 3:25 PM
americanbankingnews.com logoZafgen Inc (ZFGN) Issues Earnings Results, Misses Expectations By $0.05 EPS
www.americanbankingnews.com - May 10 at 5:22 PM
americanbankingnews.com logoZafgen Inc (ZFGN) Raised to Buy at Zacks Investment Research
www.americanbankingnews.com - May 10 at 11:40 AM

Social

Chart

Zafgen (ZFGN) Chart for Friday, September, 22, 2017

This page was last updated on 9/22/2017 by MarketBeat.com Staff